

Mark A J M Hendriks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1089493/publications.pdf>

Version: 2024-02-01

5
papers

118
citations

1937685

4
h-index

2053705

5
g-index

5
all docs

5
docs citations

5
times ranked

196
citing authors

#	ARTICLE	IF	CITATIONS
1	CD20-selective inhibition of CD47-SIRP1 α doesn't eat me signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab. <i>Oncolimmunology</i> , 2018, 7, e1386361.	4.6	58
2	Bispecific antibody approach for EGFR-directed blockade of the CD47-SIRP1 α doesn't eat me immune checkpoint promotes neutrophil-mediated trogoptosis and enhances antigen cross-presentation. <i>Oncolimmunology</i> , 2020, 9, 1824323.	4.6	25
3	Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade. <i>Journal of Investigative Dermatology</i> , 2019, 139, 2343-2351.e3.	0.7	20
4	Bispecific antibody CD73xEpCAM selectively inhibits the adenosine-mediated immunosuppressive activity of carcinoma-derived extracellular vesicles. <i>Cancer Letters</i> , 2021, 521, 109-118.	7.2	12
5	Cancer cells under immune attack acquire CD47-mediated adaptive immune resistance independent of the myeloid CD47-SIRP1 α axis. <i>Oncolimmunology</i> , 2021, 10, 2005344.	4.6	3